Office Evolution Partners with Eco-Friendly ISONAS to Improve Client Security and Access Technology
...allows all of its clients seamless access to all nine locations 24/7. This system provides unmatched flexibility for all of its clients; with a single fob they can now use any location at any time without having to carry multiple access cards or keys. Office Evolution clients now have nine full time off...Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
... pegylated recombinant form of human G-CSF, and an fob of the FDA-approved product Neulasta(R), which had...e progress we are making in the development of our fob portfolio, utilizing our unique protein drug devel...lopment path for INS-20." The initiation of this fob trial is the second of two planned for 2008 as par...Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
...ay provided an update of the status of its initial fob development candidates, INS-19 (a fob of Neupogen(R)) and INS-20 (a fob of Neulasta(R)) which represent combined 2007 sale...Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
...ealthcare providers; -- An enhanced Insmed website containing enhanced fob resources and updates; -- Interactive advocacy program utilizing user-... healthcare issue." "Insmed is very much at the forefront of the evolving fob industry," continued Dr. Allan. "We have the capacity and intellectual capi...Clearview Ulra Fecal Occult Blood FOB
Description: Clearview ULTRA FOB is a rapid, two-step immunochemical test for the detection of fecal occult blood....Insmed Announces First Quarter 2009 Financial Results
...his $122.7 million improvement was primarily due to the gain on sale of our fob assets to Merck which was partially offset by increases in SG&A and R&a...nts was due to the $127.8 million in net proceeds from the sale of Insmed's fob assets to Merck, which was minimally offset by $2.1 million utilized to fun...Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
... "The sale of our fob assets to Merck represents a watershed moment for ...ing an increase in clinical trial activity for our fob and IPLEX(TM) programs. SG&A Expenses increas... the higher activity as our clinical trials in the fob and IPLEX(TM) areas advanced. SG&A Expenses f...Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
... pegylated recombinant form of human G-CSF, and an fob of the FDA-approved product Neulasta(R), ...ey Allan, President and CEO of Insmed. "Our second fob candidate, INS-20, has entered the clinic, and dem...al to be an initial entrant into the emerging U.S. fob marketplace. In addition, we are working closely w...Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
...resident and CEO of Insmed. "Most importantly, our fob initiatives have received strong scientific valida...ure that we make informed decisions for moving our fob program forward, and advancing the development of ...e in clinical trial costs this last quarter as our fob and IPLEX(TM) programs gained momentum. The increa...Insmed Retains RBC Capital Markets as Strategic Financial Advisor
...first few initial entrants in the rapidly evolving fob marketplace. Insmed's most advanced follow-on bi...ranulocyte Colony Stimulating Factor or G-CSF), an fob of Neupogen(R), and INS-20 (Peg G-CSF), an fob of Neulasta(R), recorded combined 2007 brand sales...Insmed Announces First Quarter 2008 Financial Results
...a clinical trial for Insmed's most advanced fob candidate, INS-19 (Granulocyte Colony Stimulating Factor or G-CSF), a fob of the FDA-approved product Neupogen(R), wh...possible development of legislation to establish a fob regulatory pathway and; -- Participated...Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
...5 years of biotechnology experience, as President of the Company's fob program in order to most effectively leverage Insmed's scientific ...h indicated a $9 billion annual market potential for the Company's fob candidates whose corresponding innovator products' patents expire ...CIO Leadership Series: Brian Brylow, Robert W. Baird & Co.
...to all of Baird associates, consists of a web-based front end that allows associates to connect to their portfolio of applications using a SecurID key fob and their Baird security credentials. Each associate has specific applications that they are entitled to use, Brylow said, making the tool ideal for t...